Cibus, Inc. Logo

Cibus, Inc.

Develops & licenses gene-edited, non-transgenic traits to the seed industry for resilient crops.

CBUS | US

Overview

Corporate Details

ISIN(s):
US13173L1070 (+1 more)
LEI:
Country:
United States of America
Address:
6455 NANCY RIDGE DRIVE, 92121 SAN DIEGO
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Cibus, Inc. is an agricultural biotechnology company that develops and licenses plant traits to the seed industry. The company utilizes a proprietary, high-throughput precision gene-editing technology to create specific, value-added traits in a non-transgenic manner, significantly accelerating the development timeline compared to traditional breeding. Cibus focuses on creating more resilient and sustainable crops by developing traits that provide herbicide tolerance, disease resistance, and pest resistance. Its business model involves partnering with seed companies to integrate these traits into major crops like canola, soybean, and wheat, generating revenue through licensing agreements and royalties.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cibus, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cibus, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cibus, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CAMBRIDGE COGNITION HOLDINGS PLC Logo
Digital brain health assessment platform for CNS clinical trials and research.
United Kingdom
COG
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan
4575
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland
CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America
CDIO
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America
SAVA
Celcuity Inc. Logo
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
United States of America
CELC
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM
Celyad Oncology SA Logo
Clinical-stage biotech developing CAR T therapies for solid and blood cancers.
Belgium
CYAD

Talk to a Data Expert

Have a question? We'll get back to you promptly.